AI Science Tracker

Machine-learning pipeline identifies antimicrobial hexapeptides

Zhejiang University · 12 Jan 2023 · biology

Discovery

Machine-learning pipeline identifies antimicrobial hexapeptides

A sequential machine-learning pipeline screened virtual libraries of 6–9-residue peptides and identified three leading antimicrobial hexapeptides. The paper reports activity against multidrug-resistant clinical isolates and therapeutic effects in a mouse bacterial-pneumonia model. These are laboratory and animal results, not clinical efficacy.

Technology: Sequential machine-learning pipeline for peptide selection, classification, ranking and activity regression

Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.

Result, AI contribution and limits

Evidence context (descriptions follow the cited sources; test type is a catalog classification):

  • Publication status: Peer-reviewed paper
  • Test type: direct test
  • Tested: The authors report a sequential machine-learning pipeline over virtual 6–9 amino-acid sequence space; the leading three identified hexapeptides were tested against clinical multidrug-resistant isolates and in a mouse bacterial-pneumonia model.
  • Still unknown: The mouse model and reported comparison with penicillin do not establish human efficacy. The PubMed primary metadata gives journal online date 2023-01-12; no earlier pre-2020 version is identified in the reviewed primary material.
  • AI role: Sequential learned modules selected, classified, ranked and regressed peptide candidates from the virtual sequence library; the reported three lead hexapeptides are outputs of that workflow.

Evidence sources: https://www.nature.com/articles/s41551-022-00991-2 · https://pubmed.ncbi.nlm.nih.gov/36635418/

Source checked · editorial details

The source page was checked against this entry. Independent confirmation is not assessed by this label.

Source type: paper. Paper: linked separately.

Review date: 17 Nov 2026. Review scope: Primary Nature indexed article text and PubMed abstract/metadata/affiliation record for the ML hexapeptide screening study, its January 2023 publication date and reported mouse pneumonia assays..

Editorial assessment: Impact 3/5 · Validation 3/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.

Follow-up and relationships

No follow-up recorded; this is not a claim that no follow-up exists.

Follow-up review scope and date are not recorded.

No source-supported relationships recorded.

Open in the full catalog for filters, charts and related discoveries.